The first two authors contributed equally to this study In order to understand the immunogenicity of a tumor-associated antigen (TAA), Ras family small GTP binding protein (RalA) in hepatocellular carcinoma (Hee), autoantibody responses to RalA were evaluated by enzyme-linked immunosorbent assay (ELISA), Western blotting and indirect immunofluorescence assay in sera from patients with Hee and sera from normal individuals. Immunohistochemistry (IHC) study with tissue array slides was also preformed to analyze protein expression profiles of RalA in Hee and control tissues. This study demonstrated that RalA had a relative higher frequency of autoantibody response in Hee (20.1%) compared to liver cirrhosis (3.3%), chronic hepatitis (0%), and normal individuals sera (0%). RalA also showed a stepwise increased expression from normal liver tissues (26.7%), liver cirrhosis tissues (45.0%) to Hee tissues (63.3%). Sensitivity and specificity of anti-RalA antibody in detection of Hee was 20.1% and 99.3%, respectively. The data suggested that RalA might contribute to liver malignant transformation, and could be used as a potential tumor marker in Hee detection.
Although there is rapid increase in the number of serological analysis of recombinant cDNA expression libraries (SEREX) defined antigens, a great majority of these antigens have, however, been found to have no direct relevance to cancer. For example, some of them could be the antigens associated with pre-existing non-cancer diseases, some might be related to necrotic products of cancer cells, and some antigens are even the self-proteins normally expressed in human tissues. Existing evidence has demonstrated that a significant portion of the currently identified tumor antigens by SEREX are autoantigens of this kind (l). To address the issue regarding the immunogenicity of the identified antigens, our aim is to focus on strategies to narrow down the relevant tumor-related antigens and evaluate them to be used as serological diagnostic markers or therapeutic targets of immuno-therapy. Particularly, serological screening from normal individuals, cancer patients and patients with nonneoplastic diseases is of critical importance. Using recombinant protein as target antigen, screening human sera in a large scale by immunoassay such as ELISA or Western blot, can provide such indications Variables Results All HCC sera were collected at the time of initial cancer diagnosis, when the patients had not yet received treatment with any chemotherapy or radiation therapy. The patients with CH and LC had been followed for at least 18 months since the date ofblood collection to exclude individuals with primary biliary cirrhosis and asymptomatic HCC. Normal human sera were collected during annual health examinations from people who had no obvious evidence of malignancy. Due to the regulations concerning studies ofhuman subjects, the patient's name and identification number were blinded to investigators, and some clinical information for sera used in this study was not currently available. This study was approved by the Institutional Review Board of Xia'men University and collaborating institutions. Monoclonal mouse anti-RalA was commercially purchased (BD Biosciences, San Diego, CA, USA). 
MATERIALS AND METHODS

Sera and antibodies
Sera from 129 patients with HCC, 30 patients with CH, 30 patients with LC, and 82 normal human sera were obtained from the serum bank of the Tumor Cell Engineering Laboratory of Xia'men University (Fujian Province, P.R. China). All HCC patients were diagnosed according to the criteria described in a previous study (5) . General information regarding HCC patients is shown in of the serological reaction pattern of sera from patients with or without cancer (2) .
Ral, a member of the Ras super-family of small GTPases, is encoded by two genes, RalA or RalB. RalA has tissue-specific pattern of expression in developing organs. Tissue recombination experiments have shown that Ral expression is increased by interaction in the lung, indicating that RalA expression is functionally regulated (3). RalA cDNA was identified in a previous study with HepG2 cDNA expression library screening (4) . In the subsequent study, cDNA encoding RalA was subcloned into an expression vector, and the recombinant protein was further expressed and purified. Using recombinant RalA as a target antigen, the immunoreactivity of RalA was evaluated by ELISA and Western blot in sera from patients with hepatocellular carcinoma (HCC), liver cirrhosis (LC), and chronic hepatitis (CH), as well as normal human sera. Indirect immunofluorescence assay with cell line and immunohistochemistry (IRC) study with tissue array slides were performed to analyze the protein expression profiles of RalA in HCC tissues. produce a fusion protein with N-terminal 6x histidine and T7 epitope tags. Recombinant RalA protein was further expressed in E. coli BL21 (DE3) cells and purified using nickel column chromatography. The protocol used for highlevel expression and purification of 6x His-tagged proteins were performed as described (QIAGEN Inc, Valencia, CA, USA). Elution buffer (8M urea, O.IM NaH 2P04 , O.OlM Tris, pH4.5) was used to elute the recombinant protein.
The purified recombinant proteins were further analyzed by electrophoresis on SDS-PAGE, and identified by Western blot using anti-histidine antibody, and also by commercial monoclonal anti-RaIA antibody.
Enzyme-linked immunosorbent assay (ELISA)
Purified recombinant protein was diluted in phosphate-buffered saline (PBS) to a final concentration of 0.5Jlg/ml and coated onto a 96 well microtiter plate (Dynatech Laboratories, Alexandria, VA). Human sera diluted 1:200 were incubated in the antigen-coated wells. Horseradish peroxidase (HRP)-conjugated goat antihuman IgG (Caltag Laboratories, San Francisco, CA) and the substrate 2, 2'-azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (Boehringer Manheim GmbH, Mannheim, FRG) were used as detecting reagents. Each serum sample was tested at least 2 times, and the average OD value at 405 nm was used for data analysis. The cutoff value designating positive reaction was the mean OD of 82 normal human sera (NHS) +3SD. Each run of ELISA included 8 NHS selected to represent a range of absorbance above and below the mean of 82 NHS, and whose OD average is close to the mean OD of 82 normal human sera. The inclusion of these normal controls is to normalize all absorbance values in other runs of ELISA. All positive sera were further confirmed by Western blotting.
Western blotting
Western blotting was performed essentially as described (6) . Purified recombinant RalA protein was electrophoresed on SDS-PAGE and transferred onto a nitrocellulose membrane paper. After pre-blocking with PBS containing 5% non-fat dry milk and 0.05% Tween-20 (PBST) for 30 min at room temperature, the nitrocellulose strips were incubated for 90 min at room temperature with a 1:200 dilution of serum. HRP-conjugated goat anti-human IgG was applied as secondary antibody at a 1: 3,000 dilution. Immunoreactive bands were detected using the ECL kit (Amersham, Arlington Heights, IL) according to the manufacturer's instructions.
Indirect immunofluorescence assay
Identification of autoantibody against RalA in HCC sera was performed using methanol-and acetone-fixed HepG2 cell slides. In brief, HepG2 cells were grown on coverslips, fixed for 5 min at -20°C in 100% methanol, and permeabilized for 3 min at -20°C in 100% acetone. Monoclonal anti-RalAantibody (25 ul) at 1:2,000 dilutions was added as positive control. Human cancer sera (1:200 dilution) which show positive reactivity in ELISA and the same sera which had been preabsorbed with antibody were added to HepG2 cell-coated wells on the slide. Normal human serum and PBS were used as negative and blank controls, respectively. After incubation of one hour in a humidity chamber, the FITC-conjugated goatanti-human IgG (Caltag Laboratories, San Francisco, CA, USA) was applied as secondary antibody (l :80 dilution). The slides were examined with a confocal laser-scanning microscope (LSMS PASCAL, Carl Zeiss GmbH, lena, Germany).
Absorption ofantibodies with recombinant protein
Sera were diluted (l :200) and incubated for 2 h at room temperature with 15 ug recombinant proteins. The mixture was centrifuged at 1O,000xg for 10 min, and the supernatant was used for ELISA analysis and immunofluorescence assay. The experiment was repeated four times, and average OD values were used for data analysis.
Immunohistochemistry (IHC) with tissue array slides
Superfrost plus tissue slides which contain 60 paraffin-embedded HCC specimens, 40 LC tissue specimens and 30 normal liver tissue specimens were commercially purchased (Cybrdi, Bethesda, MD, USA) and used for RalA antigen detection. Antigen retrieval was performed by microwaveheating methods in a citrate-based antigen retrieval solution (BioGenex, San Ramon, CA) according to the manufacturer's recommendation. Non-specific protein binding sites were blocked by 1.5% normal horse serum for 30 min in a humidifier. The sections were incubated with monoclonal anti-RalA antibody at optimal concentration (l :2,000 dilution) which was determined by initial immunohistochemistry on cancer tissue slides (William Beaumont Medical Center in El Paso). Biotinylated secondary antibody, ABC (Avidin: Biotinylated enzyme Complex), and DAB (3,3'-diaminobenzidine) substrate were used as detecting reagents according to the manufacturer's recommendation (Vector Laboratories, Burlingame, CA). The slides were counterstained with hematoxylin, fixed by Scott's solution and dehydrolyzed with different concentrationa of EtoH and Citrisolvent. Finally, the slides were mounted with permount mounting medium and observed under microscope. All staining results were also confirmed by our collaborator from the University of Texas Medical Branch in Galveston, Texas, who is a medical pathologist. 
Immunofluorescence staining pattern of RalA in HepG2 cells
To further confirm the specificity of autoantibody response to RalA in HCC sera, and also explore the intracellular location of RalA protein, HCC sera with anti-RalA positive in ELISA were also examined using HepG2 cells as substrate by indirect immunofluorescence assay. As shown in Fig. 2 , a representative HCC serum with anti-RalA antibody positive in ELISA had a cytoplasmic staining pattern with more intense staining in the perinuclear regions, which was a similar pattern to that shown by monoclonal RalA antibody. The same HCC serum was pre-absorbed with recombinant RalA protein, and subsequently applied for immunofluorescence assay, and then the fluorescent signal was significantly reduced.
Expression of RalA in HCC tissues by immunohistochemistry with tissue array
In this study, the expression profile of RalA in HCC, LC and normal liver tissues were examined by immunohistochemistry with tissue array slides. Tissue array slides including 60 HCC tissue specimens, 40 LC tissue specimens, as well as 30 normal liver tissue specimens, were commercially available for this study. The concentration of monoclonal anti-RalA used for immunostaining the tissue specimens were determined by initial immunohistochemistry study on tumor tissue slides, and subsequently, the tissue-array slides were stained with monoclonal anti-RalA antibody. The hematoxylin and eosin (H&E) staining showed the histopathology of the same specimen. As shown in Table III , the results indicated that there was a stepwise increased frequency ofRalA overexpression Autoantibody to RalA (%) No. tested Type of sera Prevalence ofautoantibody to RalA in HCC As described in Materials and Methods, the cDNA encoding RalA was amplified by PCR from a human EST clone, and the PCR products were sub-cloned into the pET28 expression vector which was designed to produce a fusion protein with N-terminal 6x histidine and T7 epitope tags. In the subsequent study, the full-length recombinant RalA protein was used as coating antigen in ELISA to detect antibodies against this protein in sera from patients with different conditions. Sera from 129 patients with HCC, 30 patients with LC, and 30 patients with CH as well as 82 NHS were available for this study. As demonstrated in Table  II , of 129 HCC sera analyzed, the frequency of autoantibody to RalA was 20.1% (26/129), which was significantly higher than that in sera with LC (3.3%), CH (0%), and NHS (0%) (P<O.OI). The sensitivity and specificity of anti-RalA antibody as marker in detection of HCC were 20.1% and 99.3%, respectively. Most of the positive HCC sera showed OD values over 2-fold above the cut-off (mean+3S.D. of NHS), indicating that antibody responses to the antigen in some HCC patients were quite robust and not just mildly elevated. The ELISA result was confirmed by Western blotting analysis. Fig. 1 shows four representative HCC sera which have positive reaction to RalA in ELISA, and also have strong reactivity in Western blotting analysis. The specificity of recombinant RalA in ELISA was also confirmed by antibody absorption study (data not shown). In a further study, the data showed that 67 of 129 (51.9%) HCC sera had abnormal serum AFP level (> 1OOng/ml). If anti-RalA and AFP were simultaneously used as diagnostic markers, 79 of 129 (61.3%) HCC patients could be correctly identified.
Statistical analysis
Thefrequency of antibodies in eachcohort of patients' serawas compared using theX 2 testwithYate's correction, and two significant levels (0.01 and 0.05) were used. Sensitivity and specificity were calculated as described (7) . sufficient to induce activation of NF-KB-dependent gene expression and cyclin D1 transcription, two key convergence points for mitogenic and survival signaling (15) (16) . Another study also found a constitutively activated form of RalA GTPaseactivated transcription factor Stat3 through the activation of c-Src (17) . In the current study, RalA was identified as a possible tumor-associated antigen by immunoscreening a cDNA expression library with serum antibodies from an HCC patient. In a subsequent study, the purified recombinant RalA protein was used as target antigen, and the autoantibody response to this protein in sera from patients with HCC and precursor conditions, such as liver cirrhosis and chronic hepatitis, was investigated.
RalA was more commonly activated compared to other major Ras effector pathway in distinct cancer cell lines, and knockdown of RalA expression impeded, if not abolished, the ability of human cancer cells to form tumors. Thus, activation ofRalA plays a critical role in Ras-induced tumorigenesis (18) . RalA was also reported to play an important role in epidermal growth factor (EGF)-mediated cell motility and it potentially contributes to tumor metastasis in human cancer (19) (20) (21) . Taken together with the evidence provided by our study that the frequency of antibody to RalA was significantly higher in HCC sera (20.1%) compared to other conditions (LC, CH and NHS), it suggested that RalA might contribute to liver malignant transformation, and could be used as a potential tumor marker in HCC detection. Data from our study also demonstrate in HCC tissues (63.3%, 38/60), LC tissues (45.0%, 18/40) and normal liver tissues (26.7%, 8/30). The frequency of RalA expression in HCC tissues was significantly higher than that in normal liver tissues (p<O.Ol). The frequency of RalA positive staining in HCC grade I, II and III were 62.5% (5/8), 69.23% (27/39), and 46.1% (6/13), respectively. Due to the small sample size of tissues with different grades in this tissue array slide, it is difficult to establish a statistical association between RalA expression and tumor grade. Fig. 3 showed the representative positive and negative immunostaining pattern of RalA in HCC tissues. Because of lack of data regarding different clinical stages of HCC tissues in this commercial tissue array slide, it was not possible for us to establish a statistical correlation between RalA expression and clinical stages in this study. P value relative to normal tissue: **P< 0.01
DISCUSSION
Ral proteins are small GTPase and work downstream of Ras protein signaling pathway (8) . The monomeric Ral (Ras-like) GTPases have been indirectly implicated in mitogenic regulation and Ras-mediated oncogenic transformation (9-10). Ral-GEFs (Ral guanine nucleotide exchange factors), one of the primary Ras binding proteins or effectors propagate oncogenic Ras signals by activating the RalA and RalB (11) (12) . It has been shown that RalA and RalB collaborate to maintain tumorigenicity through regulation of both proliferation and survival (13) (14) . The mechanism by which Ral GTPase may contribute to proliferation and transformation is still poorly understood. that if both RalA and AFP are simultaneously used as diagnostic markers, 61.3% HCC patients could be correctly identified, suggesting that RalA might be an independent but also a supplementary serological marker for the diagnosis ofHCC. Due to the small size of samples, whether the antibody response to RalA in HCC sera is correlated with the clinical significance remains to be established. In the current study, the expression profiles of RalA in HCC, liver cirrhosis, and normal liver tissues were extensively evaluated by immunohistochemistry assay with tissue microarray (TMA) slides. Our results show that the expression of RalA in HCC tissues (63.3%) was significantly higher than that in normal liver tissues (26.7%). Analysis on the frequency of positive RalA staining in HCC tissues with different grades has not revealed any significant correlation between RalA expression and cancer grades due to the limited number oftissue specimens in this study, especially the small sample size of tissues with grade I and III. The finding also suggests that the emerging of the expression of RalA is associated with HCC progression , and may playa role in HCC transformation. The higher imrnunogenicity of RalA in HCC sera is probably related to the abundant expression of RalA in HCC tissue, which makes them more accessible for presentation within MHC molecules and thus, more available to the immune system for immune recognition. The mechanism for RalA contributing to cell proliferation and transformation is still unknown, but evidence from other studies supported that expression of gain-of-function of RalA can affect several mitogenic regulatory cascades, including nuclear factor-KB (16), Src (17) , and phospholipase D1 (PLD I) (22) . Although there are strong indications that RalA may be functionally associated with HCC tumorigenesis, however, the non-restricted HCC expression, especially the higher expression in a benign condition, such as liver cirrhosis, tempered its usefulness as a target for HCC immunotherapy.
With the rapid development of new techniques in searching TAAs, a bunch of novel antigenic proteins have been identified as potential tumor antigens. A systemic analysis to validate the target antigens and assessment of clinical application is essentially important, especially in the area of biomarkers for diagnosis and the targets for immunotherapy. As mentioned above, despite the improvement of therapeutic methods in HCC, such as surgery, chemotherapy, radio-therapy, ethanol injection therapy, and trans-arterial embolization, a high case fatality rate still remains a problem which is partially due to the precursor liver diseases that limit the use of chemotherapeutic drugs, rapid intra-liver spread and out-liver metastasis. Therefore, a new approach, such as immunotherapy, is urgently needed. However, the critical selection of immunotherapeutic targets relies on the restricted tumor expression of tumor antigens that will be recognized by the host immune system, leading to tumor rejection. The lower expression in normal tissue and vital organs therefore avoids the autoimmune damage accompanied by immunotherapy. Our study demonstrates that there was a significantly increased autoimmune response to RalA in HCC sera compared to normal human sera. Whether or not RalA expression is specifically in HCC, and can contribute ideal targets for HCC immunotherapy still needs to be established. Many studies demonstrate that an immunohistochemistry approach can provide such a method to analyze the expression profile of targeted tumor antigen by staining tissue specimens with monoclonal or polyclonal antibody (23) . In the present study, the expression profile of RalA in different tissue types, such as the tissues from patients with HCC and LC as well as normal liver tissues, was examined and evaluated in tissue microarray (TMA) slides using an immunohistochemistry approach. The tumor antigens which show restricted HCC expression are assumed to be ideal candidates for diagnostic markers as well as potential targets for cancer immunotherapy. Tissue microarray technology takes advantage of tissue cylinders (diameter 0.6 mm) derived from hundreds of different primary tumor blocks and subsequently brought into one empty "recipient" paraffin block. It allows high throughput molecular profiling of diagnostic or predictive markers in cancer specimens and rapid validation of novel potential candidates identified from genomic and proteomic analyses in a large number oftumor samples by immunohistochemistry. Most importantly, data from tissue microarray can be evaluated in combination with databases containing pathological and clinical information related to individual specimens (24) . The functional significance of individual tumor antigen, thus, can be assessed at a global scale of cancer development. Due to the higher immunogenecities of RalA in HCC sera, we propose that the increased HCCspecific expression of the antigen may strengthen its usefulness, not only as diagnostic markers but also feasible targets for HCC immunotherapy.
In conclusion, data from this study demonstrate that RalA has a significantly higher immunogenicity in HCC patients compared to patients with liver cirrhosis and chronic hepatitis as well as normal individuals. Whether RalA can be used as diagnostic marker in HCC detection, and the underlining mechanism of how this antigen induces humoral immune response in HCC patients remain to be investigated. Further study with a comprehensive analysis on RalA expression profile in HCC may provide more insight into how it is involved in the tumorigenesis of HCC.
